Recent studies have conferred that the RAD51C and RAD51D genes, which code for the essential proteins involved in homologous recombination, are ovarian cancer (OC) susceptibility genes that may explain genetic risks in high-risk patients. We performed a mutation analysis in 171 high-risk BRCA1 and BRCA2 negative OC patients, to evaluate the frequency of hereditary RAD51C and RAD51D variants in Czech population. The analysis involved direct sequencing, high resolution melting and multiple ligation-dependent probe analysis. We identified two (1.2%) and three (1.8%) inactivating germline mutations in both respective genes, two of which (c.379_380insG, p.P127Rfs*28 in RAD51C and c.879delG, p.C294Vfs*16 in RAD51D) were novel. Interestingly, an indicative family cancer history was not present in four carriers. Moreover, the ages at the OC diagnoses in identified mutation carriers were substantially lower than those reported in previous studies (four carriers were younger than 45 years). Further, we also described rare missense variants, two in RAD51C and one in RAD51D whose clinical significance needs to be verified. Truncating mutations and rare missense variants ascertained in OC patients were not detected in 1226 control samples. Although the cumulative frequency of RAD51C and RAD51D truncating mutations in our patients was lower than that of the BRCA1 and BRCA2 genes, it may explain OC susceptibility in approximately 3% of high-risk OC patients. Therefore, an RAD51C and RAD51D analysis should be implemented into the comprehensive multi-gene testing for high-risk OC patients, including early-onset OC patients without a family cancer history.

Department of Oncology 1st Faculty of Medicine Charles University Prague General University Hospital Prague and Military University Hospital Prague Prague Czech Republic

Institute of Biochemistry and Experimental Oncology 1st Faculty of Medicine Charles University Prague Prague Czech Republic

Institute of Biochemistry and Experimental Oncology 1st Faculty of Medicine Charles University Prague Prague Czech Republic; Institute of Biology and Medical Genetics 1st Faculty of Medicine Charles University Prague and General University Hospital Prague Prague Czech Republic

See more in PubMed

Weissman SM, Weiss SM, Newlin AC (2012) Genetic testing by cancer site: ovary. Cancer J 18: 320–327. 10.1097/PPO.0b013e31826246c2 PubMed DOI

Epidemiology of malignant tumors in the Czech Republic. Available: http://www.svod.cz. Accessed 18 December 2014.

Oosterwijk JC, de Vries J, Mourits MJ, de Bock GH (2014) Genetic testing and familial implications in breast-ovarian cancer families. Maturitas 78: 252–257. 10.1016/j.maturitas.2014.05.002 PubMed DOI

Ramus SJ, Harrington PA, Pye C, DiCioccio RA, Cox MJ, Garlinghouse-Jones K, et al. (2007) Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. Hum Mutat 28: 1207–1215. PubMed

Somyajit K, Subramanya S, Nagaraju G (2010) RAD51C: a novel cancer susceptibility gene is linked to Fanconi anemia and breast cancer. Carcinogenesis 31: 2031–2038. 10.1093/carcin/bgq210 PubMed DOI PMC

Masson JY, Tarsounas MC, Stasiak AZ, Stasiak A, Shah R, McIlwraith MJ, et al. (2001) Identification and purification of two distinct complexes containing the five RAD51 paralogs. Genes Dev 15: 3296–3307. PubMed PMC

Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V et al. (2010) Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 42: 406–409. 10.1038/ng.570 PubMed DOI

Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D et al. (2010) Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 42: 410–414. 10.1038/ng.569 PubMed DOI

Coulet F, Fajac A, Colas C, Eyries M, Dion-Miniere A, Rouzier R et al. (2013) Germline RAD51C mutations in ovarian cancer susceptibility. Clin Genet 83: 332–336. 10.1111/j.1399-0004.2012.01917.x PubMed DOI

Loveday C, Turnbull C, Ruark E, Xicola RM, Ramsay E, Hughes D et al. (2012) Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet 44: 475–476. 10.1038/ng.2224 PubMed DOI

Golmard L, Caux-Moncoutier V, Davy G, Al Ageeli E, Poirot B, Tirapo C et al. (2013) Germline mutation in the RAD51B gene confers predisposition to breast cancer. BMC Cancer 13: 484 10.1186/1471-2407-13-484 PubMed DOI PMC

Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K et al. (2014) Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 121: 25–33. 10.1002/cncr.29010 PubMed DOI

Schnurbein G, Hauke J, Wappenschmidt B, Weber-Lassalle N, Engert S, Hellebrand H et al. (2013) RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families. Breast Cancer Res 15: R120 10.1186/bcr3589 PubMed DOI PMC

Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR et al. (2011) Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 43: 879–882. 10.1038/ng.893 PubMed DOI PMC

Pelttari LM, Kiiski J, Nurminen R, Kallioniemi A, Schleutker J, Gylfe A et al. (2012) A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer. J Med Genet 49: 429–432. 10.1136/jmedgenet-2012-100852 PubMed DOI PMC

Wickramanayake A, Bernier G, Pennil C, Casadei S, Agnew KJ, Stray SM et al. (2012) Loss of function germline mutations in RAD51D in women with ovarian carcinoma. Gynecol Oncol 127: 552–555. 10.1016/j.ygyno.2012.09.009 PubMed DOI PMC

Thompson ER, Rowley SM, Sawyer S, kConfab, Eccles DM, Trainer AH et al. (2013) Analysis of RAD51D in ovarian cancer patients and families with a history of ovarian or breast cancer. PLoS One 8: e54772 10.1371/journal.pone.0054772 PubMed DOI PMC

Gutierrez-Enriquez S, Bonache S, de Garibay GR, Osorio A, Santamarina M, Ramón y Cajal T et al. (2014) About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants. Int J Cancer 134: 2088–2097. PubMed

Janatova M, Kleibl Z, Stribrna J, Panczak A, Vesela K, Zimovjanova M et al. (2013) The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer. Cancer Epidemiol Biomarkers Prev 22: 2323–2332. 10.1158/1055-9965.EPI-13-0745-T PubMed DOI

Pohlreich P, Zikan M, Stribrna J, Kleibl Z, Janatova M, Kotlas J et al. (2005) High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Breast Cancer Res 7: R728–R736. PubMed PMC

Kleibl Z, Novotny J, Bezdickova D, Malik R, Kleiblova P, Foretova L et al. (2005) The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic. Breast Cancer Res Treat 90: 165–167. PubMed

Kleibl Z, Havranek O, Hlavata I, Novotny J, Sevcik J, Pohlreich P et al. (2009) The CHEK2 gene I157T mutation and other alterations in its proximity increase the risk of sporadic colorectal cancer in the Czech population. Eur J Cancer 45: 618–624. 10.1016/j.ejca.2008.09.022 PubMed DOI

Sopik V, Akbari MR, Narod SA (2014) Genetic testing for RAD51C mutations: in the clinic and community. Clin Genet: In press. PubMed

Baker JL, Schwab RB, Wallace AM, Madlensky L (2015) Breast Cancer in a RAD51D Mutation Carrier: Case Report and Review of the Literature. Clin Breast Cancer 15: e71–e75. 10.1016/j.clbc.2014.08.005 PubMed DOI

Walsh T, Lee MK, Casadei S, Thornton AM, Stray SM, Pennil C et al. (2010) Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A 107: 12629–12633. 10.1073/pnas.1007983107 PubMed DOI PMC

Pennington KP, Swisher EM (2012) Hereditary ovarian cancer: beyond the usual suspects. Gynecol Oncol 124: 347–353. 10.1016/j.ygyno.2011.12.415 PubMed DOI

Rashid MU, Muhammad N, Faisal S, Amin A, Hamann U (2014) Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan. Breast Cancer Res Treat 145: 775–784. 10.1007/s10549-014-2972-0 PubMed DOI

Blanco A, Gutierrez-Enriquez S, Santamarina M, Montalban G, Bonache S, Balmaña J et al. (2014) RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families. Breast Cancer Res Treat 147: 133–143. 10.1007/s10549-014-3078-4 PubMed DOI

Stratton MR, Rahman N (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40: 17–22. PubMed

Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, Holli K et al. (2011) RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet 20: 3278–3288. 10.1093/hmg/ddr229 PubMed DOI

Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes